Dihydrotestosterone (DHT/Stanolone/Androstanolone) for Androgen Therapy — Anabolic Steroids

Overview

Dihydrotestosterone (DHT, also known as stanolone or androstanolone) is the primary biologically active metabolite of testosterone, formed by the action of 5-alpha-reductase enzymes (type I and type II) on testosterone in target tissues including the prostate, skin, hair follicles, and central nervous system. DHT binds the androgen receptor with 3-10 times greater affinity than testosterone and has a 5-fold slower dissociation rate from the AR, making it the most potent natural androgen. Critically, DHT cannot be aromatized to estrogen because the 5-alpha-reduced A-ring structure prevents it from being a substrate for aromatase (CYP19A1). This non-aromatizable property makes DHT valuable in specific clinical scenarios where androgenic effects are needed without estrogen production. DHT is approved in several countries (primarily France, Belgium, and other European nations) as a topical gel formulation (Andractim 2.5%) for the treatment of micropenis in neonates/children, gynecomastia, and androgen deficiency. In the United States, DHT products are not FDA-approved, though compounding pharmacies occasionally prepare DHT cream formulations. The clinical pharmacology of DHT is well-characterized: applied topically, it provides local androgenic effects with limited systemic exposure. When used systemically (injectable stanolone), DHT produces potent androgenic effects including virilization, prostate stimulation, sebaceous gland activation, and accelerated androgenetic alopecia (male pattern baldness) in genetically susceptible individuals. DHT has a short elimination half-life (approximately 30-60 minutes for unconjugated DHT), necessitating frequent injection or sustained-release formulations for systemic use. In performance-enhancement contexts, DHT derivatives (stanozolol, oxandrolone, drostanolone) are far more commonly used than pure DHT due to their improved pharmacokinetic profiles. Pure DHT is occasionally used for its anti-estrogenic properties (competitive AR occupancy without estrogen conversion) and its effects on neurosteroid-mediated mood, confidence, and aggression.

Indications

• Approved (select countries): Micropenis treatment in neonates — topical Andractim gel
• Approved (select countries): Gynecomastia treatment — topical application
• Approved (select countries): Androgen deficiency states — where non-aromatizable androgen needed
• Off-label: Anti-estrogenic androgen therapy (no aromatization to estrogen)
• Research: Investigation of AR-selective androgenic signaling
• Performance: Occasional use for mood, confidence, and androgen-mediated CNS effects

Mechanism of Action

DHT administered as topical gel (Andractim 2.5%) for local effect or as injectable stanolone for systemic exposure. Topical route provides sustained local androgen levels with limited systemic absorption. Injectable route requires frequent dosing due to 30-60 minute half-life of unconjugated DHT

Dosing

Evidence Grade

GRADE B

Safety & Contraindications

• Potent androgenic side effects — accelerated male pattern baldness in susceptible individuals
• Prostate stimulation — benign prostatic hyperplasia risk with chronic use
• Severe acne and sebaceous gland hyperactivity
• Cannot be converted to estrogen — may cause estrogen deficiency symptoms if used alone
• Suppresses endogenous testosterone via HPG axis negative feedback
• Short half-life (~30-60 minutes unconjugated) requires frequent dosing or topical sustained release
• Not FDA-approved in the United States — limited to compounding pharmacies
• Virilization risk in women — voice deepening, clitoromegaly, hirsutism
• Lipid profile perturbation — HDL suppression with systemic use
• Schedule III controlled substance (classified with AAS)
• Topical formulations can transfer to others via skin contact